The CASBAH Study

Central Nervous System Health of Broadly Neutralising Antibodies and Interruption of Antiretroviral Therapy in Persons with HIV

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN16138250

Enrollment

Registered

2026-03-11

Start date

2026-03-16

Completion date

Unknown

Last updated

2026-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Human immunodeficiency virus [HIV] disease Infections and Infestations

Interventions

This is a prospective, observational, single-centre clinical study. Twenty (20) persons with HIV, who have stopped daily oral antiretroviral therapy and are participating in a clinical trial which in

Eligibility

Sex/Gender

All

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Documented HIV-1 infection 2. Full capacity to provide signed informed consent 3. Participating in a clinical trial which involves the administration of bNAbs 4. Has received at least one infusion of a bNAb or placebo 5. Able to comply with the study procedures in the opinion of the investigator

Exclusion criteria

Exclusion criteria: 1. Cerebral infections (including AIDS defining illnesses) 2. Contraindication for MRI examination (e.g. claustrophobia, metal implants, physically unable to lie flat) 3. Contraindication to lumbar-puncture examination (at the discretion of the investigator)

Countries

England, United Kingdom

Contacts

Public ContactNicki Doyle

n.doyle@imperial.ac.uk+44 (0)20 7594 3351

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Apr 3, 2026